General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients...

Asthma deaths levels increase by a quarter in a decade

Asthma deaths levels increase by a quarter in a decade

July 26 2018 There were 1,320 deaths due to asthma in England and Wales in 2017, the highest...

NPA and Age UK ask for help on building polypharmacy dossier

NPA and Age UK ask for help on building polypharmacy dossier

July 25 2018 The National Pharmacy Association is asking its members for case studies on...

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

July 24 2018 New Health Secretary Matt Hancock has called for investment in primary care and...

NHS Digital seeks views on SCR with Additional Information

NHS Digital seeks views on SCR with Additional Information

July 24 2018 A survey to assess the benefits and/or disadvantages of health professionals...

  • General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    Tuesday, 31 July 2018 15:31
  • Asthma deaths levels increase by a quarter in a decade

    Asthma deaths levels increase by a quarter in a decade

    Thursday, 26 July 2018 15:08
  • NPA and Age UK ask for help on building polypharmacy dossier

    NPA and Age UK ask for help on building polypharmacy dossier

    Wednesday, 25 July 2018 13:46
  • Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Tuesday, 24 July 2018 12:53
  • NHS Digital seeks views on SCR with Additional Information

    NHS Digital seeks views on SCR with Additional Information

    Tuesday, 24 July 2018 12:41

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

A inspection imageJune 19 2018

A practice-based audit will seek to explore community pharmacy’s contribution in supporting girls and women of childbearing potential who need to take valproate medicines.

Launched by the Company Chemists’ Association, the audit tool has been designed to help pharmacists and their teams review and reflect on their current practice and to assess what changes may need to be made. The first phase of the audit will begin in July, and the second phase will begin in November.

The audit follows on from changes to the medicines licences for valproate medicines introduced earlier this year meaning the products should not be used in pregnancy and women of child bearing potential. Those taking valproate should be made aware of the risks of teratogenicity and be on a planned pregnancy progamme as appropriate.

While the audit is being sent out to CCA member pharmacies, the Association is urging all community pharmacy teams to participate. The audit materials can be downloaded from the CCA site (link below).

Kate Livesey, the CCA’s Policy & Programmes Manager, said: “Community pharmacy teams play a vital role in the care of patients taking these high-risk medicines. Given the importance of this year’s topic, we would like to see pharmacy teams from all across the country getting involved in our audit and reviewing their current practice.  

“We’re really keen to build a body of evidence from across the whole sector that demonstrates what pharmacy teams are doing to improve care and minimise the risk of harm around valproate in pregnancy.”  

PSNC has lent its support to the launch of the audit. Alastair Buxton, Director of NHS Services, at PSNC said: “Patient safety is always a priority in community pharmacy and this audit provides a great opportunity to make a difference to patient safety by focussing on a high-risk medicine associated with birth defects and developmental disorders. 

“Community pharmacy teams are in an ideal position to provide information and advice to women and girls who have been prescribed this medicine, ensuring they get the crucial support they need. This audit is an excellent option for contractors to complete to meet the Community Pharmacy Contractual Framework requirement to undertake a practice-based clinical audit.”

Links:
CCA announcement      
CCA Valproate audit resource   
PSNC comment             

Practice News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...